Sanofi's Trading Volume Surges 88.55% to 1.92 Billion, Ranks 457th Amid Stock Price Decline

On March 25, 2025, Sanofi's trading volume reached 1.92 billion, marking an 88.55% increase from the previous day, placing it 457th in the day's stock market rankings. Sanofi's stock price fell by 0.86%, marking the fifth consecutive day of decline, with a total decrease of 6.19% over the past five days.

Sanofi announced that the U.S. Food and Drug Administration (FDA) has accepted the regulatory submission for tolebrutinib, a potential treatment for patients with multiple sclerosis, for priority review. This designation reduces the review period by four months, with a final decision expected by September 28, 2025. If approved, tolebrutinib would be the first brain-penetrant BTK inhibitor to treat non-relapsing secondary progressive multiple sclerosis (nrSPMS) and slow disability accumulation independent of relapse activity in adult patients.

Tolebrutinib's breakthrough therapy designation by the FDA is based on positive results from the HERCULES phase 3 study in adults with non-relapsing secondary progressive multiple sclerosis. The PERSEUS phase 3 study of tolebrutinib in patients with primary progressive multiple sclerosis is currently ongoing, with study results anticipated in the second half of 2025. Sanofi noted that tolebrutinib is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority.